Brain+

0,014

DKK

0 %

Mindre end 1K følgere

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

0%

-7,69%

-41,94%

-65,53%

-69,13%

-73,55%

-97,57%

-

-98,95%

Brain + er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling til behandling af demens og Alzheimers. Produktporteføljen omfatter f.eks. Kognitiv stimuleringsterapi. Forretningen drives med den største tilstedeværelse i Europa.

Markedsværdi

16,31 mio. DKK

Aktieomsætning

22,9 t DKK

Omsætning

200 t

EBIT %

-5.830 %

P/E

-

Udbytteafkast, %

-

Finanskalender

28.8

2025

Delårsrapport Q2'25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse24.6.2025, 12.11

Brain+ A/S announces first day of trading in new shares following the TO 5 warrant exercise

Selskabsmeddelelse18.6.2025, 09.22

Brain+ A/S announces the outcome of its series TO 5 warrant exercise

Selskabsmeddelelse10.6.2025, 07.58

Brain+ A/S has received commitments to cover 100% of its TO 5 warrants, securing DKK 5.9 million in gross proceeds

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse6.6.2025, 14.56

Invitation to investor webinar featuring Antony Hall: How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla

Pressemeddelelse6.6.2025, 08.51

New research underscores the effects of Cognitive Stimulation Therapy, supporting its role for UK care homes to comply with care quality statements

Pressemeddelelse5.6.2025, 09.49

Brain+ signs agreement with UK care home group Majesticare deploying Ayla for effective dementia care

Selskabsmeddelelse2.6.2025, 13.49

Brain+ A/S announces the exercise price for its warrants of series TO 5

Selskabsmeddelelse30.5.2025, 14.22

Brain+ A/S - Minutes of Annual General Meeting

Pressemeddelelse28.5.2025, 06.46

Brain+ A/S: Leading UK dementia care authority, Antony Hall, joins Brain+ as Strategic Advisor

Pressemeddelelse26.5.2025, 06.48

Brain+ A/S: Brain+ signs its second UK sales agreement on Ayla with Park Homes UK Group

Selskabsmeddelelse15.5.2025, 21.27

Brain+ A/S convenes the Annual General Meeting for 2025

Pressemeddelelse5.5.2025, 07.00

Brain+ A/S: Brain+ selected for the NHS Dementia Innovators Programme in the UK

Selskabsmeddelelse29.4.2025, 18.19

Brain+ A/S: Brain+ publishes its Annual Report for 2024

Selskabsmeddelelse16.4.2025, 09.15

Brain+ A/S: Brain+ appoints CCO Devika Wood as new CEO

Selskabsmeddelelse9.4.2025, 06.50

Brain+ A/S: Brain+ announces directed issue of units to convertible loan providers and guarantors

Pressemeddelelse3.4.2025, 06.41

Brain+ A/S: Contract signed with Copenhagen Municipality on extended and expanded access to Ayla

Selskabsmeddelelse2.4.2025, 06.47

Brain+ A/S: Brain+ announces outcome of unit rights issue

Pressemeddelelse26.3.2025, 07.35

Brain+ A/S informs of last day to subscribe in its ongoing rights issue of units

Pressemeddelelse25.3.2025, 11.56

Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group

Pressemeddelelse19.3.2025, 13.44

Brain+ A/S: Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.